The U.S. Food and Drug Administration has approved Rextovy, a 4 mg naloxone hydrochloride nasal spray, for over-the-counter use, expanding access to a critical medication used to reverse opioid overdose. According to the FDA, consumers will be able to purchase Rextovy without a prescription at pharmacies, convenience stores, and online, marking another step forward in broadening access to naloxone as the nation continues to confront the opioid crisis.
The approval is significant for healthcare leaders, pharmacists, and community prevention programs because naloxone remains one of the most important tools in overdose prevention. Wider retail availability can help place the medication in more homes, clinics, schools, and public settings, while also reducing barriers for family members, caregivers, and community organizations seeking quick access to an emergency overdose-reversal product. The FDA said Rextovy is approved for the emergency treatment of known or suspected opioid overdose and should be administered by adults or under adult supervision.